Group 1 - The core viewpoint of the news highlights the positive performance of the Chinese pharmaceutical and medical device innovation index, with significant gains in specific stocks and a new development plan for traditional Chinese medicine [1] - The China Securities Regulatory Commission and eight other departments have issued a plan to promote the high-quality development of traditional Chinese medicine, aiming to approve a batch of innovative traditional Chinese medicines and cultivate ten major traditional Chinese medicine products by 2030 [1] - The overall funding congestion in the innovative drug sector has slightly decreased compared to Q2, with some funds temporarily withdrawing from innovative drugs, while the medical device sector remains stable and is expected to attract more investment [1] Group 2 - The China Medical and Medical Device Innovation Index (931484) includes 30 listed companies with good profitability and growth potential, reflecting the overall performance of profitable and growth-oriented pharmaceutical and medical device companies [2] - As of January 30, 2026, the top ten weighted stocks in the index account for 63.9% of the total index, including companies like WuXi AppTec, Mindray Medical, and Hengrui Medicine [2]

风险提示：基金有风险，投资需谨慎。基金管理人承诺以诚实信用、勤勉尽责的原则管理和运用基金资 产，但不保证本基金一定盈利，也不保证最低收益。基金管理人提醒投资人基金投资的"买者自负"原 则，在做出投资决策后，基金运营状况与基金净值变化引致的投资风险，由投资人自行负担。基金的过 往业绩及其净值高低并不预示其未来业绩表现，基金管理人管理的其他基金的业绩不构成对本基金业绩 表现的保证。投资人购买基金，既可能按其持有份额分享基金投资所产生的收益，也可能承担基金投资 所带来的损失。投资人应当认真阅读《基金合同》《招募说明书》等基金法律文件，全面认识本基金的 风险收益特征和产品特性，并根据自身的投资目的、投资期限、投资经验、资产状况等判断基金是否和 投资人的风险承受能力相适应，理性判断市场，谨慎做出投资决策。本材料中相关信息来源于基金管理 人认为可靠的公开资料，相关观点、评估和预测仅反映当前的判断，后续可能有所变化。本材料所含任 何市场观点的内容皆基于相应的假设条件，而任何假设条件都可能随时发生变化。基金管理人不承诺、 不保证任何具有预测性质的市场观点必然得以实现。材料中提及的个股不构成投资推荐或建议。ETF基 金的二级市 ...

消息面上，近日，由脑机交互与人机共融海河实验室周鹏智慧中医团队牵头，天津中医药大学第一附属 医院、天津市滨海新区中医医院、天津中医药大学、天中依脉公司等多家优势单位联合研发的全国首个 脑控针灸融合神经康复装备平台"神工-华佗"落地。团队创新性研发了"脑机接口+智能穿戴式针灸"融合 技术，相关研究已获国家载人航天实验项目等多项前期项目支撑。 截至2026年2月4日 13:13，中证医药及医疗器械创新指数(931484)成分股方面涨跌互现，东阿阿胶领涨 3.35%，恩华药业上涨1.14%，康弘药业上涨1.03%；特宝生物领跌。医疗创新ETF(516820)最新报价0.36 元。 华金证券认为，政策端持续加码——国家药监局首次将"人工智能医疗器械"列为四大重点发展领域，技 术端DeepSeek-R1等开源大模型显著降低开发门槛，共同推动国内AI+医疗市场进入高速增长通道；全 球AI医疗市场规模预计2022–2030年CAGR达35.5%，至2030年将达1553亿美元。 从资金净流入方面来看，医疗创新ETF近13天获得连续资金净流入，最高单日获得4182.65万元净流 入，合计"吸金"2.46亿元，日均净流入达18 ...

截至2026年2月4日 10:58，中证医药及医疗器械创新指数(931484)成分股方面涨跌互现，东阿阿胶领涨 3.31%，恩华药业上涨1.62%，新和成上涨1.57%；特宝生物领跌。医疗创新ETF(516820)最新报价0.36 元。 从资金净流入方面来看，医疗创新ETF近13天获得连续资金净流入，最高单日获得4182.65万元净流 入，合计"吸金"2.46亿元，日均净流入达1890.95万元。（数据来源：Wind） 消息面上，阿斯利康宣布未来十年在中国投资150亿美元，重点投向细胞治疗与放射性偶联药物 （RDC）两大前沿方向，涵盖北京、上海的战略研发中心建设，以及无锡、泰州、青岛、北京等地生 产基地扩建与新建，并计划将中国高技能员工队伍扩展至超2万人。 风险提示：基金有风险，投资需谨慎。基金管理人承诺以诚实信用、勤勉尽责的原则管理和运用基金资 产，但不保证本基金一定盈利，也不保证最低收益。基金管理人提醒投资人基金投资的"买者自负"原 则，在做出投资决策后，基金运营状况与基金净值变化引致的投资风险，由投资人自行负担。基金的过 往业绩及其净值高低并不预示其未来业绩表现，基金管理人管理的其他基金的业绩不构成对本 ...

Group 1 - The core point of the article is that Ailis has updated the registration status of its self-developed small molecule targeted drug, Fumetinin Mesylate Tablets, for the treatment of EGFR exon 20 insertion mutation NSCLC to "Approval Completed - Awaiting Certification" [2] - The indication is for adult patients with locally advanced or metastatic NSCLC who have progressed on or are intolerant to prior platinum-based chemotherapy and have confirmed EGFR exon 20 insertion mutations [2] - Phase II clinical trials showed an overall response rate (ORR) of 44.3%, a median progression-free survival (PFS) of 8.3 months, and a median overall survival (OS) of 22.9 months, indicating potential for expanding patient coverage and increasing sales [2]

| 药品名称 | 甲磺酸伏美替尼片 | | --- | --- | | 申报事项 | 境内生产药品注册上市许可 | | 药品注册分类及子类 | 化学药品 类 2.4 | | 加快注册上市程序 | 优先审评审批程序 | | 受理号/备案号 | CXHS2500084 | | 获批适应症 | 本品适用于既往经含铂化疗治疗时或治疗后出现疾病 进展，或不耐受含铂化疗，并且经检测确认存在表皮生 | | | 长因子受体（EGFR）20 号外显子插入突变的局部晚期 | | | 或转移性 的成人患者。 NSCLC | 证券代码：688578 证券简称：艾力斯 公告编号：2026-002 上海艾力斯医药科技股份有限公司自愿披露 关于甲磺酸伏美替尼片EGFR 20号外显子插入突变NSCLC 二线治疗适应症药品注册进展的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海艾力斯医药科技股份有限公司（以下简称"公司"）近日从国家药品监 督管理局（以下简称"国家药监局"）药品业务应用系统查询获悉，公司提交的 甲磺酸伏美替尼片EGFR 20号外 ...

Core Viewpoint - The domestic AI-assisted medical technology is advancing, with significant developments in the approval of innovative medical devices and the application of AI in healthcare, indicating a potential for rapid growth in the AI+ healthcare market [1][2]. Group 1: Market Performance - As of February 3, 2026, the CSI Medical and Medical Device Innovation Index (931484) increased by 0.57%, with notable gains from stocks such as Aimeike (+4.07%), Jianfan Bio (+2.36%), and Xinhengcheng (+2.29%) [1]. - The Medical Innovation ETF (516820) also rose by 0.57%, with the latest price reported at 0.36 yuan [1]. Group 2: AI in Healthcare - AI applications in smart healthcare are becoming mature, particularly in medical imaging diagnostics, where AI assists doctors in improving interpretation efficiency [2]. - Recent AI medical products have accelerated their market entry, including the "Cervical Cell Digital Pathology Image Auxiliary Diagnosis Software" approved in January 2026 and the "Yuan Zhi" model from United Imaging, which achieved over 95% accuracy in complex lesion diagnosis [2]. - The combination of technological iteration and policy support is expected to drive rapid growth in the domestic AI+ healthcare market [2]. Group 3: Index Composition - The CSI Medical and Medical Device Innovation Index comprises 30 publicly listed companies with strong profitability, growth potential, and R&D innovation capabilities, reflecting the overall performance of profitable and growth-oriented medical and medical device companies [2]. - As of January 30, 2026, the top ten weighted stocks in the index include WuXi AppTec, Mindray Medical, and Hengrui Medicine, collectively accounting for 63.9% of the index [2].

Group 1 - The core viewpoint of the news highlights the positive performance of the medical innovation sector, with the CSI Medical and Medical Device Innovation Index showing mixed results among its constituent stocks, led by Aimeike with a 2.18% increase [1] - The Medical Innovation ETF has seen continuous net inflows over the past 12 days, with a peak single-day net inflow of 41.83 million yuan, totaling 234 million yuan, averaging 19.54 million yuan per day [1] - Policy support for the pharmaceutical industry is ongoing, with Shanghai accelerating the implementation of major industrial projects in fields such as integrated circuits, biomedicine, and artificial intelligence [1] Group 2 - The CSI Medical and Medical Device Innovation Index consists of 30 listed companies with good profitability, growth potential, and research innovation capabilities, reflecting the overall performance of profitable and growth-oriented pharmaceutical and medical device companies [2] - As of January 30, 2026, the top ten weighted stocks in the index include WuXi AppTec, Mindray Medical, and Heng Rui Medicine, accounting for 63.9% of the total index weight [2] - The success rate of Phase I clinical trials for dozens of AI-derived pipelines entering trials in 2025 is projected to be as high as 80%-90%, significantly exceeding traditional levels of 40%-65% [1]

经新华财经统计，2月2日，剔除停牌的埃夫特，科创板其余600只个股平均跌幅3.41%，平均换手率 3.34%，合计成交额2715亿元，平均振幅为5.48%。 个股表现方面，复洁科技涨停，涨幅靠前；航天宏图跌3.41%，跌幅居首。 成交额方面，澜起科技成交额137.7亿元，位居首位；ST帕瓦成交额1409万元，位居末位。 （文章来源：新华财经） 新华财经北京2月2日电科创50指数2月2日早间低开，随后震荡下挫，最终大幅收跌。至收盘时，科创50 指数报1450.9点，跌幅3.88%，指数振幅为3.87%，总成交额约866亿元。 2月2日，科创综指全日收跌3.95%，收于1760.23点，总成交额约2715亿元。 从盘面来看，剔除停牌的埃夫特，科创板其余600只个股多数下跌，高价股、低价股均普遍下跌。细分 领域来看，除少数电气设备股、专用机械股表现活跃，个别医疗保健股、环境保护股等有所上涨，其余 细分领域个股均呈普遍下跌态势。 换手率方面，思看科技换手率为24.9%，位居首位；佰仁医疗换手率为0.23%，位居末位。 ...

消息面上，2月1日，华为云正式宣布，"行业AI梦工厂"首个落地成果——智慧医疗专区亮相，同时，即 日起启动公开测试，率先开放健康管理与病理AI辅助诊断两大核心功能，面向广大医疗机构、医生及 大众开放服务与体验。该专区深度融合上海瑞金医院等顶尖医疗机构的临床经验与华为在云、AI及ICT 领域的技术积累，旨在构建一个端到端的AI赋能平台。 光大证券强调，在医保控费（DRG/DIP）与大模型技术奇点双重驱动下，AI已成为医疗新基建的核心 生产力；其中AI制药因能显著缩短研发周期、药企付费意愿最强，AI医学影像是当前落地最成熟的赛 道，而AI慢病管理和AI手术机器人则分别依托商业保险降本逻辑与医疗资源均衡逻辑，具备强国产化 替代潜力。未来竞争核心在于独家高质量私有数据与业务场景闭环能力。 医疗创新ETF紧密跟踪中证医药及医疗器械创新指数，中证医药及医疗器械创新指数从医药卫生行业的 上市公司中，选取30只盈利能力较好且具备一定成长性和研发创新能力的上市公司证券作为指数样本， 以反映兼具盈利性与成长性的医药及医疗器械上市公司证券的整体表现。 截至2026年2月2日 10:44，中证医药及医疗器械创新指数(931484)下 ...